BPC-157 and TB-500

BPC-157 vs TB-500: what's the difference?

The core difference between BPC-157 and TB-500 is mechanism: BPC-157 rebuilds tissue locally; TB-500 mobilises cells more systemically.

They're often spoken of as a pair, but they're unrelated molecules. BPC-157 is a 15-amino-acid peptide from gastric juice; TB-500 is a short synthetic fragment (commonly Ac-LKKTETQ) of the 44-amino-acid protein thymosin β4 — not the full protein, a distinction vendors routinely blur.[4]

Which is "better"?

There's no evidence-based "winner" — they're studied for different things. BPC-157 is the one with the deeper preclinical literature (especially gut and tendon); TB-500's fragment-specific human evidence is thinner still. For tendon- or gut-focused research questions, BPC-157 is the more-studied choice; for whole-body, mobility-type recovery framing, TB-500 is the one communities reach for. Either way, "better" depends entirely on the research question, and neither is a proven treatment.

BPC-157 and TB-500 blend (stack)

The "BPC-157 and TB-500 blend" is the single most-searched way these two come up — the idea being that complementary mechanisms (local repair + systemic cell migration) cover more of the recovery picture together than either alone.

How the blend is run

Community and vendor protocols typically describe running the two on the same schedule — often a daily BPC-157 amount alongside a less-frequent TB-500 amount — as a recovery "cycle." This is an anecdotal convention with no clinical-trial basis: there is no published study of a BPC-157 + TB-500 combination in humans, so any specific ratio or schedule is unverified.

What the blend is used for

In community use, the BPC-157 + TB-500 stack is reached for around soft-tissue injury and recovery — tendon and ligament strains, joint niggles, and general "repair" cycles after hard training. Those are the contexts the anecdotal reports cluster around. None are backed by human trials, and the framing is recovery-research, not treatment of any condition.

Blend ratio & amounts

Blend ratios circulated online are community figures, not derived values — we don't present a specific blend dose as established, and this page does not provide measurement or administration guidance.

Can you use BPC-157 and TB-500 together?

In research and community use, BPC-157 and TB-500 are commonly combined, and the rationale is straightforward: their mechanisms don't overlap, so in principle they address different parts of tissue recovery rather than duplicating each other.[1][4]

Is the combination tested?

No. The complementary-mechanism logic is reasonable, but it's reasoning, not data — there's no controlled human study of the two together (or, really, of either one alone for these uses). Treat "stack" claims as community practice, not validated protocol, and remember both are research-use-only and WADA-prohibited for tested athletes. It's also worth noting that even the individual peptides lack controlled human efficacy trials for these recovery uses — so a combination study was never going to exist before the singles were established. The honest status is "mechanistically plausible, clinically unproven."

BPC-157 vs TB-500 dosage

Neither has an established human dose. The community-reported figures differ by molecule and frequency:

These are peptide-community/vendor conventions, not from any controlled human trial. The difference in frequency (BPC-157 more often, TB-500 less often) reflects their different community protocols, not validated pharmacology.

Common questions

References

1. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019;377(2):153–159. PMID 30915550.
2. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011;17(16):1612–1632. PMID 21548867.
3. He L, Feng D, Guo H, et al. Pharmacokinetics … of body-protective compound 157 … in rats and dogs. Frontiers in Pharmacology, 2022;13:1026182. PMID 36588717. (BPC-157 animal PK)
4. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 2005. (mechanism of thymosin β4, the parent of the TB-500 fragment)

Sources [1–3] are BPC-157 (preclinical/animal); [4] concerns thymosin β4, the parent protein — TB-500 fragment-specific human data is absent. Dosing and blend figures are community/vendor conventions, unverified, not from these sources. Not medical or dosing advice.

For research use only. Not for human consumption. This page compares published research for educational purposes. It is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease.